265 results on '"Reckamp K"'
Search Results
2. 145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study
3. PP01.44 Long-Term Survival and Outcomes by Race from the Phase I/II trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced NSCLC: HCRN LUN13-175
4. 398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure
5. Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
6. 1047P Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI
7. EP.03G.01 Comparison of Tumor Immune Microenvironments Between Primary and Metastatic Sites in Non-Small Cell Lung Cancer
8. Activity of Ensartinib after Second Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKI): Topic: Medical Oncology: OA03.08
9. The FEN1 E359K germline mutation disrupts the FEN1–WRN interaction and FEN1 GEN activity, causing aneuploidy-associated cancers
10. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
11. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer†
12. P47.07 KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC
13. OA17.04 The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers
14. PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
15. The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers
16. A phase I study of bortezomib and temozolomide in patients with advanced solid tumors
17. 2286P COVID-19 vaccinations in cancer patients (pts): An individual participant data meta-analysis of the International Consortium on COVID vaccination in cancer
18. OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study
19. P84.08 First-line Brigatinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer: A Network Meta-Analysis
20. P76.85 Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors
21. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
22. Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial
23. 235 (PB115) - Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
24. Deploying the army interim brigade combat team. A quick-look approach for strategic force closure assessments
25. Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC
26. P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIB NSCLC: Update on LCMC3 Clinical Trial
27. OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3
28. P1.01-96 US Real-World Management of EGFR-Mutated Advanced NSCLC: Survival After First-Line EGFR-Tyrosine Kinase Inhibitor Treatment
29. P1.01-105 US Real-World Management of EGFR-Mutated Advanced NSCLC: Prescribing and Attrition Data from First-To-Second-Line Treatment
30. ES14.05 Patients Harbouring a Driven-Mutation: Pro and Patient's Perspective
31. P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy
32. P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib
33. P1.14-27 Duration of Targeted Therapy in Advanced NSCLC (aNSCLC) with Drivers Identified by Circulating Tumor DNA (ctDNA) Analysis
34. P1.01-67 Ph I/II Carboplatin, Nab-Paclitaxel and Pembrolizumab for Advanced NSCLC (HCRN LUN13-175): Outcomes by Nab-Paclitaxel Dose
35. Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial
36. PC04.02 Optimal Sequencing of EGFR TKI Therapy - 3rd Generation First
37. MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)
38. OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer
39. P2.01-06 HSP72 Expression Associates with Survival in EGFR Mutated NSCLC
40. OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC
41. Therapeutic antibodies: A new era in the treatment of respiratory diseases?
42. PD.1.03 Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data
43. Using Natural Language Processing to Identify Patients with Immune Checkpoint Inhibitor-Associated Myocarditis
44. ACTIVITY OF THE PAN-HER TYROSINE KINASE (TK) INHIBITOR DACOMITINIB (PF-00299804) IN REFRACTORY NONADENOCARCINOMA (NON-A) NON-SMALL CELL LUNG CANCER (NSCLC) AND COMPARED WITH ERLOTINIBIN THE 2ND-/3RD-LINE SETTING
45. MA 02.11 A Phase I Trial of Erlotinib and Onalespib in EGFR-mutant NSCLC: Focus on EGFR Exon 20 Insertions
46. P1.01-004 Hypertension With Brigatinib: Experience in ALTA, a Randomized Phase 2 Trial in Crizotinib-Refractory ALK+ NSCLC
47. Comprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types
48. P1.01-001 Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA Trial
49. OA03.08 Activity of Ensartinib after Second Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKI)
50. P2.03-043 A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naïve EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.